About the SEB Concept Biotechnology and SEB Läkemedelsfond fund merger
The board of SEB Funds AB made decision to merge SEB Concept Biotechnology fund into Sweden domiciled Healthcare fund SEB Läkemedelsfond on 8 September 2025.
Main information about the merger
- No action is required from investors.
- Investment value and rights remain unchanged.
- Both funds share the same investment objectives and strategies. The receiving fund SEB Läkemedelsfond will have higher allocation to sustainable investments – 20% compared to 10%. Both funds also have a similar risk profile.
- Investors will receive units in SEB Läkemedelsfond equal in value to the current holdings.
- The merger aims to simplify the fund offering and improve management efficiency and cost-effectiveness.
Fees and taxes
- No fees will be charged for redemption or sale of fund units before or after the merger.
- Redemption may have tax implications.
Unit classes and ISINs
| Merging Fund: SEB Concept Biotechnology | Receiving Fund: SEB Läkemedelsfond |
|---|---|
| C (EUR) — LU0385485148 | C (EUR) — SE0024788731 |
| D (EUR) — LU0118405827 | D (EUR) — SE0024788749 |
| D (USD) — LU2553409058 | E (USD) — SE0024788756 |
| UC (EUR) — LU2249630927 | F (EUR) — SE0024788764 |
Important dates
- 28 August 2025: Last day to redeem units in the merging fund SEB Concept Biotechnology before the merger (cut-off time applies).
- 5 September 2025: Calculation of the exchange ratio.
- 8 September 2025: Merger effective date. New units issued in the receiving fund. Subscription and redemption handled by the fund’s administration.
Fund comparison
| Feature | SEB Concept Biotechnology (Merging Fund) | SEB Läkemedelsfond (Receiving Fund) |
|---|---|---|
| Summary Risk Indicator (according to KID) | 5 | 4 |
| Benchmark Index | Nasdaq Biotechnology Index | MSCI World Health Care Net Return Index |
| Depositary | Skandinaviska Enskilda Banken AB (Luxembourg branch) | Skandinaviska Enskilda Banken AB (Stockholm) |
| Max. Management Fee (p.a.) | 0.75% - 1.5% depending on unit class | 0.75% - 1.5% depending on unit class |
| Ongoing Cost (p.a.) | Approx. 0.94% - 1.71% depending on unit class | Approx. 0.93% - 1.73% depending on unit class |
Fund standing order execution
Standing orders for units in the fund SEB Concept Biotechnology LU2249630927 will remain valid and apply to investments in the fund SEB Läkemedelsfond SE0024788764 following the merger. If the scheduled purchase date falls within the merger period (29 August to 8 September) it will be cancelled and will not be executed later.
Standing orders for units in the fund SEB Concept Biotechnology LU0385485148, LU0118405827 and LU2553409058 will not be prolonged.
More information about merger is available on the SEB group website.
Receiving fund KID: SEB Läkemedelsfond (PDF).
